Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03478514
Recruitment Status : Recruiting
First Posted : March 27, 2018
Last Update Posted : July 15, 2022
Information provided by (Responsible Party):
Alliance Foundation Trials, LLC.

Brief Summary:
The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.

Condition or disease Intervention/treatment Phase
Mantle Cell Lymphoma B Cell Lymphoma Drug: Palbociclib Drug: Ibrutinib Phase 2

Detailed Description:

Treatment will consist of:

  • Palbociclib administered at 100 mg oral once daily for 21 days on followed by 7 days off
  • Ibrutinib administered at 560 mg oral continuously

Patients will continue to receive study drugs until disease progression, unacceptable toxicity, or withdrawal of consent. If at any time one of the agents is held due to toxicity, the other agent may be continued in those patients who are receiving clinical benefit.

Response will be assessed by PET/CT and/or CT every 3 cycles while on therapy for the first year and then every 6 cycles thereafter until disease progression or at the investigator's discretion if otherwise medically indicated. A PET will be required to confirm CR. A bone marrow biopsy will be performed in patients with bone marrow involvement at the start of therapy to confirm complete response once patients have otherwise met criteria for CR.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 61 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Actual Study Start Date : September 11, 2018
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Single Arm

All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.

Ibrutinib will be administered at 560 mg oral continuously.

Drug: Palbociclib
Taken at 100 mg once daily for 21 days, followed by 7 days off
Other Name: Ibrance; PD-0332991

Drug: Ibrutinib
560 mg taken orally all patients throughout the study
Other Name: Imbruvica

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: 42 months ]
    Time interval between registration and progression or death

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 42 months ]
    time from registration to death due to any cause

  2. Duration of response [ Time Frame: 42 months ]
    Time from documentation of tumor response to disease progression

  3. Overall Response Rate [ Time Frame: 42 Months ]
    Proportion of patients with reduction in tumor burden of a predefined amount

  4. Complete Response [ Time Frame: 42 Months ]
    Disappearance of all non-target lesions and normalization of tumor marker level

  5. Toxicity: Incidence and severity of adverse events by summaries of toxicity data/contingency tables [ Time Frame: 42 Months ]
    Evaluation of incidence and severity of adverse events by summaries of toxicity data/contingency tables

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must have histologically or cytologically confirmed MCL as defined by the World Health Organization. All patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry (IHC) for cyclin D1.
  2. Subjects must have measurable disease defined as at least one tumor lesion of at least 1.5 cm by CT or MRI, PET positive lesion(s) or a peripheral blood CD5+, CD19+ lymphocyte count of at least 5,000 cells/µL.
  3. Subjects must have received at least one prior systemic therapy.
  4. Subjects who have received prior autologous stem cell transplant are eligible. Patients that have undergone prior allogeneic stem cell transplant will only be eligible if the patient is no longer taking immunosuppressive therapy and there are no significant ongoing transplant-related adverse effects.
  5. Subjects must be age ≥ 18 years
  6. ECOG performance status ≤ 2
  7. Subjects that have received either prior BTK inhibitor or CDK4/6 inhibitor will not be eligible
  8. Patients must have normal organ and marrow function as defined below:
  9. Laboratory Values:

    • ANC ≥ 1000 cells/μL;
    • Platelets ≥ 75,000 cells/μL;
    • Calculated creatinine clearance ≥30mL/min;
    • AST or ALT ≤ 2.5x ULN;
    • Total bilirubin ≤ 1.5x ULN;
    • QTc ≤ 480 ms
  10. Subjects must be able to provide written, informed consent
  11. Subjects must have recovered from adverse events to ≤ grade 1 from prior therapies
  12. Subjects must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption
  13. Subjects may be receiving prednisone at a maximum dose of 20 mg orally daily for symptom control.
  14. Serum or urine pregnancy test must be negative within 7 days of starting study treatment in women of childbearing potential. Women of childbearing potential and men with female partners who are able to become pregnant are required to use a highly effective form of barrier contraception for the duration of the study and for 90 days after the last dose of study drug. Adequate contraception is defined as abstinence or two forms non hormonal contraception, which is a combination of two forms of the following:

    • Condom with spermicidal foam/gel/cream/suppository
    • occlusive cap (diaphragm or cervical vault caps) with spermicidal
    • non hormonal intrauterine device (IVD)
  15. No evidence of active hepatitis B or C infections (i.e., no positive serology for anti-HBc or anti-HCV antibodies)
  16. HBV seropositive patients (HBsAg +) are eligible if they are closely monitored for evidence of active HBV infection by HBV DNA testing and receive suppressive therapy with lamivudine or other HBV suppressive therapy until 6 months after the last rituximab dose.
  17. Patients with HIV infection are eligible, provided they meet the following:

    • No evidence of coinfection with hepatitis B or C
    • CD4+ cell count ≥ 400/mm3
    • No evidence of resistant strains of HIV
    • If not on anti-HIV therapy, HIV viral load < 10,000 copies HIV RNA/mL If on anti-HIV therapy, HIV viral load < 50 copies HIV RNA/mL
    • No history of AIDS-defining conditions
    • No use of strong CYP3A4/5 inhibitors or inducers

Exclusion Criteria:

  1. Subjects with known or suspected CNS involvement
  2. Concurrent therapy with other investigational products
  3. History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib
  4. Subjects receiving any medications or substances that are strong or moderate inhibitors or strong inducers of CYP3A isoenzymes within 7 days of starting study treatment (See Appendix II)
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements.
  6. Subjects with myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities are not eligible. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
  7. Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to registration, irrespective of the method of contraception used, are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Breastfeeding should be discontinued prior to study entry.
  8. Subjects must agree to use barrier contraceptive methods throughout the study period up until at least 90 days post last palbociclib dose.
  9. Subjects with clinically significant history of liver disease, including viral or other known hepatitis, current alcohol abuse, or cirrhosis, etc.
  10. Subjects with another active malignancy that limits survival
  11. Subjects with a bleeding diathesis are not eligible.
  12. Subjects with transfusion-dependent thrombocytopenia are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03478514

Layout table for location contacts
Contact: Quality Management and Compliance 617-732-8727

Layout table for location information
United States, California
City of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Principal Investigator: Leslie Popplewell, MD         
United States, Maryland
University of Maryland, Greenebaum Comprehensive Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Principal Investigator: Jennie Y. Law, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Jeremy Abramson, MD         
United States, Michigan
St. Joseph Mercy Hospital Cancer Care Center Recruiting
Ypsilanti, Michigan, United States, 48197
Principal Investigator: Tareq Al Baghdadi, MD         
United States, New York
Roswell Park Comprehensive Cancer Center Recruiting
Buffalo, New York, United States, 14263
Principal Investigator: Pallawi Torka, MD         
Weill Cornell Medical College Active, not recruiting
New York, New York, United States, 10065
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599
Principal Investigator: Anne Beaven, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Principal Investigator: Kami Maddocks, MD         
United States, Rhode Island
Lifespan Cancer Institute - Rhode Island Hospital Withdrawn
Providence, Rhode Island, United States, 02903
United States, South Carolina
Medical University of South Carolina - Hollings Cancer Center Recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Irl Brian Greenwell, MD         
Spartanburg Medical Center/Gibbs Cancer Center Withdrawn
Spartanburg, South Carolina, United States, 29303
Sponsors and Collaborators
Alliance Foundation Trials, LLC.
Layout table for investigator information
Principal Investigator: Monica Bertagnolli, MD Alliance Foundation Trials, LLC.
Study Chair: Kami Maddocks, MD Ohio State University

Layout table for additonal information
Responsible Party: Alliance Foundation Trials, LLC. Identifier: NCT03478514    
Other Study ID Numbers: AFT-32
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: July 15, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alliance Foundation Trials, LLC.:
mantle cell lymphoma
B-cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action